JP2009535036A5 - - Google Patents

Download PDF

Info

Publication number
JP2009535036A5
JP2009535036A5 JP2009507945A JP2009507945A JP2009535036A5 JP 2009535036 A5 JP2009535036 A5 JP 2009535036A5 JP 2009507945 A JP2009507945 A JP 2009507945A JP 2009507945 A JP2009507945 A JP 2009507945A JP 2009535036 A5 JP2009535036 A5 JP 2009535036A5
Authority
JP
Japan
Prior art keywords
time point
gene expression
level
hcv
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009507945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535036A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/067421 external-priority patent/WO2007127801A2/en
Publication of JP2009535036A publication Critical patent/JP2009535036A/ja
Publication of JP2009535036A5 publication Critical patent/JP2009535036A5/ja
Pending legal-status Critical Current

Links

JP2009507945A 2006-04-26 2007-04-25 C型肝炎ウイルス感染症のバイオマーカー Pending JP2009535036A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79552006P 2006-04-26 2006-04-26
PCT/US2007/067421 WO2007127801A2 (en) 2006-04-26 2007-04-25 Hepatitis c virus infection biomarkers

Publications (2)

Publication Number Publication Date
JP2009535036A JP2009535036A (ja) 2009-10-01
JP2009535036A5 true JP2009535036A5 (enExample) 2010-06-17

Family

ID=38656353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507945A Pending JP2009535036A (ja) 2006-04-26 2007-04-25 C型肝炎ウイルス感染症のバイオマーカー

Country Status (13)

Country Link
US (1) US20100028874A1 (enExample)
EP (1) EP2016195A4 (enExample)
JP (1) JP2009535036A (enExample)
KR (1) KR20090023360A (enExample)
CN (1) CN101479389A (enExample)
AU (1) AU2007244824A1 (enExample)
CA (1) CA2650616A1 (enExample)
IL (1) IL194920A0 (enExample)
MX (1) MX2008013796A (enExample)
NO (1) NO20084954L (enExample)
NZ (1) NZ573052A (enExample)
RU (1) RU2008146518A (enExample)
WO (1) WO2007127801A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
KR20110074870A (ko) * 2008-09-24 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 간염을 치료하기 위한 peg-인터페론, 리바비린 및 vx-950을 포함하는 치료 요법
WO2011132086A2 (en) 2010-04-21 2011-10-27 MeMed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
CN115054687A (zh) * 2014-08-22 2022-09-16 广州英恩迈生物医药科技有限公司 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
WO2017149547A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
US11274345B2 (en) 2016-06-07 2022-03-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
CN110448548B (zh) * 2018-05-08 2023-05-05 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
CN111333710B (zh) * 2020-03-04 2021-12-03 暨南大学 C20orf24蛋白缺失突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients
US7892735B2 (en) * 2004-12-30 2011-02-22 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia spectrum disorders in the sulfotransferase 4a (sult4a) gene

Similar Documents

Publication Publication Date Title
JP2012513479A5 (enExample)
JP2007517543A5 (enExample)
JP2009511595A5 (enExample)
JP2015024998A5 (enExample)
JP2011511804A5 (enExample)
JP2007504269A5 (enExample)
JP2009526751A5 (enExample)
JP2008518943A5 (enExample)
JP2004525179A5 (enExample)
TW200618810A (en) Treatment of respiratory syncytial virus (RSV) infection
CA2515293A1 (en) Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
JP2005532372A5 (enExample)
JP2012504632A5 (enExample)
JP2005537234A5 (enExample)
JP2009517473A5 (enExample)
JP2007505773A5 (enExample)
JP2007522237A5 (enExample)
JP2017515854A5 (enExample)
JP2010520200A5 (enExample)
RU2010153688A (ru) Режим дозирования телапревира
CY1110182T1 (el) Ιδεβενονη για τη θεραπεια των μυϊκων δυστροφιων
JP2020529995A5 (enExample)
JP2012503669A5 (enExample)
JP2009503045A5 (enExample)